Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan

MLA

Katsuyuki Fukutake, et al. “Inhibitor Development, Safety and Efficacy of Advate® among Previously Treated Patients with Hemophilia A in a Postmarketing Surveillance in Japan.” International Journal of Hematology, vol. 109, Jan. 2019, pp. 336–45. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........c465bfe3b4f44bef2f756d10a51f8c31&authtype=sso&custid=ns315887.

APA

Katsuyuki Fukutake, Hiroshi Takagi, Werner Engl, Junki Takamatsu, Tadashi Matsushita, Morio Arai, Midori Shima, Akira Shirahata, Haruhiko Uchikawa, Keiji Nogami, Akira Yoshioka, & Masashi Taki. (2019). Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan. International Journal of Hematology, 109, 336–345.

Chicago

Katsuyuki Fukutake, Hiroshi Takagi, Werner Engl, Junki Takamatsu, Tadashi Matsushita, Morio Arai, Midori Shima, et al. 2019. “Inhibitor Development, Safety and Efficacy of Advate® among Previously Treated Patients with Hemophilia A in a Postmarketing Surveillance in Japan.” International Journal of Hematology 109 (January): 336–45. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........c465bfe3b4f44bef2f756d10a51f8c31&authtype=sso&custid=ns315887.